VLA1553, commercially known as Ixchiq, has received USFDA clearance and will be launched in India — which has seen high number of chikungunya cases — after ‘regulatory talks with DCGI’.
Trial of live-attenuated vaccine VLA1553 was conducted in US, with high seroprotection rates observed in participants up to 180 days after vaccination. Study published in 'The Lancet'.
Trials for the vaccine, which International Vaccine Institute is developing in partnership with Bharat Biotech, are also expected to begin in Panama and Colombia by September.
Researchers from Chulalongkorn University in Thailand find that chikungunya strain identified in Thailand has mutations that originated in India and Bangladesh
In the storm around Sinauli, many academics dismissed claims of chariots being found. And the public misinterpreted the chariots as a device planted by the govt to fortify Hindutva.
Naidu’s summit brings in MoUs on same scale as Jagan’s, but CM says his plans built on speed, certainty & investor trust, with escrow accounts, simplified incentives & real-time oversight.
Without a Congress revival, there can be no challenge to the BJP pan-nationally. Modi’s party is growing, and almost entirely at the cost of the Congress.
COMMENTS